Last reviewed · How we verify
nucleoside analogues
At a glance
| Generic name | nucleoside analogues |
|---|---|
| Also known as | NAs |
| Sponsor | Beijing Ditan Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The Treatment of PD-1 Antibody Combined With Peg-IFNα in NAs-suppressed CHB Patients (NA)
- Chronic Hepatitis b Patients Switch to tAf After Discontinuation of Nucleoside Analogue (PHASE4)
- 10119473 -VIROMARKERS HDV Biomarkers Study
- DOR/TDF/3TC COmpared With BIC/FTC/TAF in ART-Naïve People Living With HIV and Overweight or Obesity (PHASE3)
- Halting Nucleoside Analogues in Chronic Hepatitis B (NA)
- Safety, Tolerability and Effectiveness of DTG/3TC vs BIC/TAF/FTC in PWH Without Antiretroviral Experience (PHASE4)
- Peginterferon Treatment Study for Inactive Chronic Hepatitis B Patients (PHASE4)
- The Clinical Cure Project of Chronic Hepatitis B in China (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- nucleoside analogues CI brief — competitive landscape report
- nucleoside analogues updates RSS · CI watch RSS
- Beijing Ditan Hospital portfolio CI